Protective effect of rosiglitazone on acute hepatic failure of mice induced by D-GalN and LPS

Objective To evaluate the protective effect of Rosiglitazone on the acute hepatic failure of mice induced by D-GalN and LPS and the possible mechanism.Methods Male mice were divided into three groups randomly:the normal group,the control group and the therapy group. The control group and the therapy group were injected by D-GalN / LPS,while the normal group was injected by saline; the therapy group was lavaged by Rosiglitazone 2 hours before D-GalN / LPS injection,and the control group and the normal group was lavaged by saline. Data of 24 hours survival rate,serum level of ALT,AST,histopathological changes of the liver and the mRNA expression of TNF-α and Caspase-3 in the liver was analyzed. Results Significantly higher survival rate and lower serum level of ALT and AST were found in the therapy group compared with the control (P0.05). The degree of liver injury in the therapy group was also found markedly improved accomanying with obvious decreased mRNA expression of TNF-α and Caspase-3 (P0.05).Conclusion Rosiglitazone may play an effectively protective role in the acute hepatic failure of mice. Rosiglitazone can inhibit the inflammation of liver,decrease the necrosis and the mortality of the acute hepatic failure. The possible mechanism may due to that Rosiglitazone reduced the expression of TNF-α and Caspase-3.